Search Results
Results found for "David M. Thal"
- TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi
suggesting that the selectivity of the G-protein lies in intrinsic features of the receptor rather than
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
When a compound’s off-rate is slower than its clearance, its biological effect outlives its plasma presence
- From Snapshots to Predictions: Why Mechanism of Action Matters
mechanisms with confidence Apply models to design cost-efficient, informative experiments This is more than
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
For drug discovery teams and scientists, staying ahead requires more than just reading papers—it demands
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
that sequence conceals a significant flaw; it treats FDA approval as the final checkpoint , rather than
- 📰 GPCR Weekly News, July 1 to 7, 2024
Submit your abstract today; you have less than two weeks!
- 📰 GPCR Weekly News, June 17 to 23, 2024
Epilepsy Models Biophysicists decipher functionality of adrenaline-binding receptor Tectonic plates more than
- Chemokine receptor-targeted drug discovery: progress and challenges
overexpressed and promote cancer progression, and use promiscuous non-peptide antagonists able to target more than
- Structural landscape of the Chemokine Receptor system
The chemokine system exhibits great versatility, with more than 50 chemokines interacting with over 20 Currently, there are more than 40 available structures of chemokines and their receptors in the Protein
- 📰 GPCR Weekly News, March 27 to April 4, 2023
Insights into GPCR Function Predicted Three-Dimensional Structure of the GCR1 Putative GPCR in Arabidopsis thaliana
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
directly in living cells produces data that are both more physiologically relevant and more reproducible than
- Four Reasons to Measure GPCR Signaling Bias in Drug Discovery
Rather than abandoning a target because of a harmful pathway, bias offers a different answer: design
- A central alarm system that gates multi-sensory innate threat cues to the amygdala
expressing calcitonin gene-related peptide (CGRP) in the parvocellular subparafascicular nucleus in the thalamus







